Review of secukinumab-induced adverse events of special interest and its potential pathogenesis

IF 3.7 4区医学 Q1 DERMATOLOGY

Dermatologic Therapy Pub Date : 2022-05-25 DOI:10.1111/dth.15599

Jingyao Liang, Sanquan Zhang, Qian Li, Yihui Yu, Xiaoyin Chen, Xibao Zhang

{"title":"Review of secukinumab-induced adverse events of special interest and its potential pathogenesis","authors":"Jingyao Liang, Sanquan Zhang, Qian Li, Yihui Yu, Xiaoyin Chen, Xibao Zhang","doi":"10.1111/dth.15599","DOIUrl":null,"url":null,"abstract":"Although secukinumab has demonstrated high efficacy and favorable safety in moderate-to-severe psoriasis and psoriatic arthritis, patients developing adverse events of special interest (AESI) were reported increasingly in real-world practice. A systematic literature search of the PubMed database was conducted to identify clinical studies or case reports on secukinumab-induced AESI. More than 1077 patients (aged 18–74 years) from 55 studies were reported to have 24 AESI 3 days to 96 weeks after secukinumab treatment. The four most common AESI was inflammatory bowel disease (n > 1000), eczematous drug eruption (n > 30), drug-associated vasculitis (n = 8), and drug-induced lupus erythematosus (n = 4). Most of these AESI were only mild to moderately severe and resolved after secukinumab discontinuation without or with symptomatic treatment. Secukinumab has the potential to develop a number of AESI by probably dysregulating the different expression of polar T-cell axes (Th1, Th2, Th17, Th22, and/or Treg) and driving various cytokines in some patients. Physicians should be aware of these AESI for timely diagnosis and proper treatment.","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"35 8","pages":""},"PeriodicalIF":3.7000,"publicationDate":"2022-05-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"4","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Dermatologic Therapy","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/dth.15599","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"DERMATOLOGY","Score":null,"Total":0}

引用次数: 4

Abstract

Although secukinumab has demonstrated high efficacy and favorable safety in moderate-to-severe psoriasis and psoriatic arthritis, patients developing adverse events of special interest (AESI) were reported increasingly in real-world practice. A systematic literature search of the PubMed database was conducted to identify clinical studies or case reports on secukinumab-induced AESI. More than 1077 patients (aged 18–74 years) from 55 studies were reported to have 24 AESI 3 days to 96 weeks after secukinumab treatment. The four most common AESI was inflammatory bowel disease (n > 1000), eczematous drug eruption (n > 30), drug-associated vasculitis (n = 8), and drug-induced lupus erythematosus (n = 4). Most of these AESI were only mild to moderately severe and resolved after secukinumab discontinuation without or with symptomatic treatment. Secukinumab has the potential to develop a number of AESI by probably dysregulating the different expression of polar T-cell axes (Th1, Th2, Th17, Th22, and/or Treg) and driving various cytokines in some patients. Physicians should be aware of these AESI for timely diagnosis and proper treatment.

查看原文本刊更多论文

secukinumab诱导的特殊不良事件及其潜在发病机制的综述

尽管secukinumab在中重度银屑病和银屑病关节炎中已经证明了高疗效和良好的安全性，但在现实世界的实践中，越来越多的患者报告出现特殊利益不良事件(AESI)。对PubMed数据库进行了系统的文献检索，以确定secukinumab诱导的AESI的临床研究或病例报告。来自55项研究的超过1077例患者(18-74岁)在接受secukinumab治疗后3天至96周出现24次AESI。四种最常见的AESI是炎症性肠病(n > 1000)、湿疹性药疹(n > 30)、药物相关性血管炎(n = 8)和药物性红斑狼疮(n = 4)。这些AESI大多数仅为轻度至中度严重，并在停药后不进行症状治疗或不进行症状治疗后消退。在一些患者中，Secukinumab可能通过失调极性T细胞轴(Th1、Th2、Th17、Th22和/或Treg)的不同表达和驱动各种细胞因子，从而有可能发展多种AESI。医生应了解这些AESI，以便及时诊断和适当治疗。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Dermatologic Therapy 医学-皮肤病学

CiteScore

7.00

自引率

8.30%

发文量

711

审稿时长

3 months

期刊介绍： Dermatologic Therapy has been created to fill an important void in the dermatologic literature: the lack of a readily available source of up-to-date information on the treatment of specific cutaneous diseases and the practical application of specific treatment modalities. Each issue of the journal consists of a series of scholarly review articles written by leaders in dermatology in which they describe, in very specific terms, how they treat particular cutaneous diseases and how they use specific therapeutic agents. The information contained in each issue is so practical and detailed that the reader should be able to directly apply various treatment approaches to daily clinical situations. Because of the specific and practical nature of this publication, Dermatologic Therapy not only serves as a readily available resource for the day-to-day treatment of patients, but also as an evolving therapeutic textbook for the treatment of dermatologic diseases.